Neurodegeneration plays a key role in multiple sclerosis (MS) contributing to long-term disability in patients. The prognosis is, however, unpredictable coloured by complex disease mechanisms which can only be clearly appreciated using biomarkers specific to pathobiology of the underlying process. Here, we describe six promising neurodegenerative biomarkers in MS (neurofilament proteins, neurofilament antibodies, tau, N-acetylaspartate, chitinase and chitinase-like proteins and osteopontin), critically evaluating the evidence using a modified Bradford Hill criteria.
Introduction
Over the last decade, we have learnt that multiple sclerosis (MS) is both an inflammatory demyelinating disorder and a neurodegenerative one. However, endeavours to answer precisely what is neurodegeneration in MS have been met with only partial success. The race to reach the finish line has meant that researchers have had to be more knowledgeable about the molecular and cellular basis of disease than ever before. Biomarkers are at the forefront of scientific discovery, medical diagnosis and treatment, and with this knowledge comes progress. A field which has greatly benefited from the use of biomarkers has been cancer research, where biomarkers such as prostate-specific antigen (PSA), for example, are currently utilized in screening programmes and personalized care.
We are currently standing at the cusp of a biomarker revolution from the perspective of critical mass, and also from a technological standpoint with more resources available to measure physiological and pathological changes in the human body than ever before.
In principle, a biomarker is a 'characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention'. 1 There needs to be a sensible format for assessing biomarkers in a critical way. Using a modified version of the Bradford Hill criteria, 2 we ask the question whether there are biomarkers of neurodegeneration that meet the criteria? Namely, is there sufficient biological plausibility (i.e. a relationship between the biomarker and effect), strength and specificity of association, consistency of findings, temporal sequence (the effect follows the change in biomarker) and a biological gradient (a proportionate relationship between the biomarker and effect)?
Biomarkers
Below, we discuss six promising biomarkers of neurodegeneration in MS ( Figure 1 ). Lesser wellcharacterized biomarkers are detailed in Table 1 .
Neurofilaments
Biological plausibility. Axonal calibre and functionality are determined by proteins such as microtubules, neurofilaments, actin and tau protein. Neurofilaments (Nf) consist of the subunits light chain (neurofilament light (NfL)): 68-70 kDa, medium chain (neurofilament medium polypeptide (NfM)): 145-160 kDa and heavy chain (neurofilament heavy (NfH)): 200-220 kDa. [33] [34] [35] Axonal damage in MS results in the release of the neurofilaments. 36 Only NfL chain and heavy chain are stable enough to be measured in immunoassays. 37, 38 Strength and specificity of association. High cerebrospinal fluid (CSF) NfL correlates with relapse activity, formation of new and gadolinium-enhancing magnetic resonance imaging (MRI) lesions 39,40 and the multiple sclerosis severity score (MSSS). 41 However, there is no strong correlation with Expanded Disability Status Scale (EDSS) or disability progression as defined by a decline in EDSS ⋟ 1, 42,43 although Trentini et al. 44 observe that it may be predictive in the short term of annual increase in EDSS. These results suggest that NfL levels in CSF from MS patients mainly reflect early axonal damage due to inflammatory mechanisms. Of note, however, CSF NfL levels have been found to be elevated in clinically isolated syndrome (CIS), relapsing-remitting multiple sclerosis (RRMS) and progressive MS implying that there is neurodegeneration induced by inflammation throughout the disease course. 42 Romme Christensen et al. 45 found that in progressive disease, NfL correlated well with the inflammatory biomarkers osteopontin (OPN) and CXCL13. By comparison, CSF NfH levels, although also elevated in CIS, 46 are even higher in patients with RRMS, primary progressive multiple sclerosis (PPMS) and secondary progressive multiple sclerosis (SPMS), and interestingly also correlated with EDSS in cross-sectional and longitudinal studies. 16, 44, 47, 48 Consequently, NfH has been proposed as a marker of chronic axonal damage.
Serum NfL levels correlate well with their CSF counterpart, raising hopes of non-invasive analysis in the near future. 49-51 Serum NfH levels have been noted to be elevated in patients with CIS that are fast converters to clinically definite MS 51 and to correlate well with clinical and MRI markers of disability in SPMS. 16 Neither NfH nor NfL is specific for MS and is released in other conditions with active neuroaxonal loss. 52, 53 Moreover, NfL has also been documented to be elevated in healthy elderly people, introducing the need for age-specific reference ranges. 54
Consistency of findings. Despite a number of investigators supporting the usefulness of neurofilament measurements as markers of neurodegeneration, there is no clear-cut distinction between the two subunits (NfL and NfH) with descriptions of both inflammatory and chronic axonal damage being reported. Indeed, there are two studies that report a relationship of NfH with relapse activity, 43,47,48 while another one shows a correlation between NfL levels and EDSS. 43 Nevertheless, potentially, the different and complementary pattern of the two proteins suggests that both could be measured simultaneously. Temporal sequence. CSF NfL reach their peak levels approximately 3 weeks after relapse onset, 36, 55 although levels appear to remain high even after a relapse (within 3 months), suggesting continued axonal degeneration; presumably Wallerian degeneration of axons distal to the MS lesion. 56 In a mouse model of MS, chronic relapsing experimental allergic encephalomyelitis (EAE), there is release of NfH into the blood compartment during both relapses and remissions, indicating a constant disease process which starts soon after the initial acute event. 16 Biological gradient. There is an association with both disease severity and future disability. High CSF NfH levels at diagnosis can predict clinically relevant disease progression at 15-year follow-up, both by EDSS progression and MRI brain atrophy, 57,58 In the short term, even serum levels of NfH have been correlated with poor walking times, with patients having elevated NfH taking nearly twice as long to complete the test as those with no detectable levels. 16 Equally, high NfL levels have been associated with poorer prognosis, 59 and as an independent prognostic biomarker for the conversion to clinically definite MS. 18 There is also an observed treatment effect. The highly active anti-inflammatory treatment natalizumab evokes an almost threefold reduction in CSF NfL levels, 47 and this effect is also demonstrated by fingolimod when switching from first-line therapies. 60 Less efficacious first-line agents are less likely to reduce NfL levels than second-line therapies. 40 CSF NfH levels also appear to respond to natalizumab treatment, albeit to a lesser extent, 61 suggesting differences in axonal protection by anti-inflammatory Strength and specificity of association. Higher levels of intrathecal IgG antibodies to NfL protein are found in MS compared with other neurodegenerative disorders 64 and are elevated even during the progressive phase of the disease. 62,65-67 Anti-NfM intrathecal production of IgM and IgG antibodies are also elevated in MS patients (relapsing-remitting, primary and secondary progressive). Increased levels of specific antibodies to NfH have also been demonstrated in CIS developing clinically definite MS. 68
Consistency of findings. Although CSF anti-NfL, -NfM and -NfH antibodies are elevated in MS, there is no clear association with disease severity or the various MS subtypes. 64,66,69 Moreover, low levels of antibodies have been detected in healthy controls, 67 particularly anti-NfM antibodies which have been detected in non-immune-mediated neurological disorders, such as headache and chronic fatigue syndrome. 64 This will limit their usefulness as a disease-specific biomarker.
The utility of anti-Nf antibodies in sera remains to be demonstrated. Ehling et al. 67 noted that anti-NfL IgG levels were elevated in both the serum and CSF in MS. However, Bartos et al. 64 found higher levels of anti-NfM in sera, unrelated to CSF anti-NfM levels, implying that disease status cannot be fully assessed by isolated serum measurements alone.
Temporal sequence of association. Anti-NfL and anti-NfH levels have been correlated with disease duration and EDSS levels; 66 although in a study by Bartos et al., 64 a similar correlation was not noted for anti-NfM levels.
Biological gradient. Reports of a relationship between anti-NfL levels and disease onset and progression in MS have been contradictory. 66, 67, 69 However, there does appear to be treatment response to natalizumab therapy, with a reduction in levels. 69 Tau protein Biological plausibility. Tau is another cytoskeleton protein found primarily in neurons, its role being to stabilize microtubules, thus facilitating fast axonal transport. 70 Like neurofilament proteins, Tau is released during axonal transection and is a potential biomarker in MS, other neurodegenerative disorders, and central nervous system (CNS) injury as a whole. 71
Strength and specificity of association. CSF tau is higher in MS compared to healthy controls, 72-74 although the finding is not specific for MS. 75 Levels are substantially higher in those with prior relapses. 76 CSF and serum measurements have been evaluated in stroke 77 and head injury, 78 as well as MS, 79 where they are also elevated. In general, serum levels are much lower than in the CSF. 80
Consistency of findings. The report of elevated tau in MS has not been a consistent finding, with three studies reporting no significant differences between MS and healthy controls. 43,81, 82 Conflicting findings have been reported with relapses versus stable subjects as well, with one study showing no difference observed between the two groups, 83 while another group found a significant positive correlation with the number of relapses before the lumbar puncture. 76
Temporal sequence of association. Two groups have demonstrated a lower CSF tau level in SPMS compared to RRMS, with a decrease in levels over the course of disease. The low levels indicate completed axonal degeneration in SPMS. 84, 85 In contrast, Brettschneider et al. 86 and Kapaki et al. 72 detected higher levels in progressive MS (PPMS and SPMS) than RRMS, suggesting continued axonal damage in progressive subtypes. Neither age nor disease duration was grossly different between the sub-populations. Therefore more work is required to look at this in greater detail.
Biological gradient. CSF tau levels correlate with the development brain atrophy 84, 87 and EDSS. 88 Serum tau has been evaluated pre-and post-mitoxantrone treatment in MS (RRMS and SPMS), but there was no significant change. 79 N-Acetylaspartate Biological plausibility. N-acetylaspartate (NAA) is an amino acid, highly expressed in neurons, oligodendrocytes and myelin that actively transfer water molecules extracellularly against a concentration gradient. 89 It is a marker of functional integrity of neuronal metabolism. 90 NAA levels could reflect either neuronal or oligodendrocyte damage. 91 Strength and specificity of association. NAA has been found to be reduced in MS compared to controls and it may be a marker of disease burden. 43, 92 Reduced NAA does not appear to be specific for MS and has also been described in Parkinson's disease, amyotrophic lateral sclerosis, Alzheimer's disease and traumatic brain injury. 37 Biological gradient. High MRI lesion loads, black hole lesion load and a decrease in brain volume are directly correlated with a reduction in CSF NAA levels. 92 Clinically, there is a negative correlation between NAA and EDSS. 43, 92, 94 There is, however, little data on a treatment effect on NAA levels. 16
Consistency of findings. A reduction in NAA in
Chitinase and chitinase-like proteins Biological plausibility. Chitinase proteins (particularly chitinase 1/chitotriosidase (CHIT1), chitinase 3-like 1 (CHI3L1) and chitinase 3-like 2 (CHI3L2)) are expressed by astrocytes and microglial cells in reaction to pro-inflammatory conditions. 95, 96 CHI3L1 was the first to be discovered as a potential biomarker through an unbiased proteomic screen of MS CSF. 97 Strength and specificity of association. Chitinases predict prognosis in early MS. The most recent evidence indicates that CHI3L2 performs better than CHI3L1 and predicts the development of MS after the first demyelinating episode, 98 although in the earlier work, CHI3L1 was mostly studied and a similar predictive capability was demonstrated. 99,100 CHI3L2 moreover correlates with other biomarkers of tissue damage (NfL, myelin basic protein (MBP), OPN), suggesting that it may be upregulated in relation with cellular damage. 98 CHI3L1 has been noted not to be specific for MS and is commonly increased in disorders where there is a possibility of active inflammation, neuromyelitis optica (NMO), HIV, stroke and Alzheimer's disease. 96, 97, [101] [102] [103] CHIT1 was found to correlate with MBP and could be a biomarker of demyelination or phagocytic activity. 98 It was also more likely to be elevated in those with mononuclear cells and evidence of intrathecal IgG synthesis in their CSF than in those without these findings. 104 Consistency of findings. Overall, all of the studies are mostly concordant. Correale et al., 101 however, did not find serum CHI3L1 levels particularly useful, noting no difference between MS and other inflammatory disorders, and healthy controls. Hinsinger et al. 105 noted that CSF CHI3L2 levels were lower in progressive MS than in RRMS, unlike CHI3L1 levels.
Temporal sequence of association. There is a trend for CSF and serum CHI3L1 to increase with disease progression, from CIS, through to RRMS and progressive MS (although this is cross-sectional sampling only): a relationship which is less clear with CHI3L2. 105 Biological gradient. Measuring chitinases at the first demyelinating event will help identify those with a poorer prognosis. 100 Novakova et al. 60 demonstrate that CHI3L1 and CHIT1 reduced after escalation in therapy to fingolimod from first-line therapies, but was essentially unchanged in those who were previously on natalizumab. In a separate proteomic analysis, natalizumab treatment for 1 year was demonstrated to reduce CSF CHI3L1 levels, suggesting that neurodegeneration-related protein CHI3L1 can be modulated by natalizumab. 106 Osteopontin Biological plausibility. Osteopontin (OPN) is a proinflammatory cytokine found in many tissues and body fluids, involved in inflammation, bone mineralization, tissue repair, tumour cell biology, atherosclerosis and renal disease. 107, 108 Its main function is to regulate cytokines, boosting interferon-gamma (IFN-g), interleukin-12 (IL-12) and decreasing interleukin-10 (IL-10) levels. As such, OPN targets T cells and polarizes toward a T helper type-1 (Th1) immune response. 109 It may also regulate T helper type-17 (Th17) autoimmune response. 110 OPN was initially implicated as a candidate biomarker for disease activity after demonstration of its upregulation in demyelination and remyelination in EAE. 111 CSF OPN levels are higher than plasma OPN levels suggesting that the OPN is preferentially secreted in the CSF. 112, 113 Strength and specificity of association. OPN levels are increased in MS cases compared to healthy controls and non-inflammatory disorders. 113 OPN levels closely correlate with clinical exacerbations in CIS and RRMS, 114, 115 and precede an increase in gadolinium-enhancing lesion number. 116 However, changes in OPN levels are not specific for MS, and due to its diverse roles, it is also increased in other neurological and non-neurological disorders, particularly those with an underlying inflammatory pathophysiology. 112, 113 Furthermore, despite the link with active disease, there appears to be no correlation with disability. 112 Consistency of findings. In a majority of cases, OPN levels are elevated in active MS, a finding that is more consistent when sampling the CSF than plasma. However, Comabella et al. 117 did note that plasma OPN levels were also elevated in SPMS cases compared with healthy controls, suggesting a role in chronic disease activity, although not consistent. 115 In addition, CSF OPN levels have also been noted to be elevated in PPMS cases, suggesting possible ongoing inflammation. 114 Timing of sampling may therefore be key, with significantly higher levels during relapse than stable disease. 117, 118 However, in a longitudinal evaluation, Runia et al. 119 did not find an association between plasma OPN levels and relapse risk, or a difference in OPN levels when sampled during active disease versus stable disease. There may also be other confounders to consider, for example, a trend toward higher plasma OPN levels in those who reported infections and other autoimmune disorders, and in those who were pregnant or postpartum during sampling. 120 Temporal sequence of association. Plasma OPN levels have been shown to rise 1 month before a rise in gadolinium-enhancing lesions, 116 and CSF OPN levels have been shown to return to baseline within 3 weeks of an acute relapse. 114 The rise in OPN levels therefore seems to precede and coincide with MS disease activity.
Biological gradient. Although there appears to be no association between OPN levels and disability, 119, 120 they are modified by anti-inflammatory therapies. In RRMS, plasma OPN levels returned to remission levels following treatment with IFNβ, 117 
Biomarker technology
The divide between hypothesis-driven biomarker analysis and hypothesis-generating biomarker discovery programmes is blurring, partly driven by the availability of new technologies over the last decade. Prior to this, analysis was reliant on laborious benchwork and the development of enzymelinked immunosorbent assays (ELISAs). Meso Scale Discovery's (MSD) electrochemiluminescence (ECL)based assays and Luminex bead technologies have led to the development of high-throughput multiplex assays with greater sensitivity, which is ideal for CSF biomarker analysis (where volume is scarce), particularly for low abundant proteins. Recently, Quanterix's Simoa analyser offers a standardized way of analysing neurodegenerative biomarkers such as NfL in sera and CSF with better correlation between the two and even more sensitivity than ECL or ELISA. 123 The latest introduction of aptamerbased technology (Somalogic), which uses singlestranded oligonucleotides to bind protein targets with high affinity, now allows quantification of at least 1300 analytes in a single sample. While proteomics remain the gold standard for discovery-level analysis, the addition of labelled peptides is a first step toward semi-quantitation of analytes. Recently, the introduction of isobaric tags now allows multiplex capability. 124 Proteomic technologies have the added advantage of allowing analysis of proteins where antibodies are not available.
Conclusion
In this review, we have critically evaluated the most promising neurodegenerative biomarkers in MS according to sufficient biological plausibility, strength and specificity of association, consistency of findings, temporal sequence and demonstration of a biological gradient. The neurofilament proteins, neurofilament antibodies, tau, NAA, chitinase and chitinase-like proteins and OPN with their inherent advantages and disadvantages have progressed our understanding of the neurodegenerative process in MS better than before. With the added advantage of the revolution in biomarker technology, it is hoped that complex and large scale data-driven models of neurodegeneration can be built in the near future. In the meantime, biomarker researchers should carefully evaluate any methodological shortcomings and progress the most promising biomarkers to the next level, that is, the ability to make predictions in individuals.
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